A Cross Sectional study on Diastolic Function and Factors Influencing Diastolic Function in Diabetes Mellitus Patients with Normal Systolic Function by Venkateswari, S
“A CROSS SECTIONAL STUDY ON DIASTOLIC 
FUNCTION AND FACTORS INFLUENCING DIASTOLIC 
FUNCTION IN DIABETES MELLITUS PATIENTS WITH 
NORMAL SYSTOLIC FUNCTION” 
 
Dissertation Submitted to 
THE TAMILNADU DR.M.G.R MEDICAL UNIVERSITY 
in partial fulfillment of the regulations 
for the award of degree of 
 
M.D.BRANCH – I 
(GENERAL MEDICINE) 
 
 
 
 
 
GOVT. CHENGALPATTU MEDICAL COLLEGE & HOSPITAL 
THE TAMILNADU DR.M.G.R MEDICAL UNIVERSITY 
CHENNAI, TAMILNADU 
 
APRIL - 2016 
CERTIFICATE 
 
This is to certify that the dissertation titled  “A CROSS SECTIONAL 
STUDY ON DIASTOLIC FUNCTION AND FACTORS INFLUENCING 
DIASTOLIC FUNCTION IN DIABETES MELLITUS PATIENTS 
WITH NORMAL SYSTOLIC FUNCTION” is the bonafide work of 
Dr.VENKATESWARI.S in partial fulfillment of the requirements for 
M.D.BRANCH – I (GENERAL MEDICINE) examination of THE 
TAMILNADU DR.M.G.R MEDICAL UNIVERSITY to be held in April 
2016. The period of study was from June 2014 to June 2015. 
 
 
Signature of the H.O.D     Signature of the DEAN 
Dr. V.R. MOHAN RAO M.D        Dr. K.MUTHU RAJ M.S 
Professor and Head     DEAN 
Department of General Medicine   Chengalpattu Medical College 
Chengalpattu Medical College    Chengalpattu 
Chengalpattu 
 
Date : 
Place : 
DECLARATION  
 
I hereby declare that this dissertation titled  “A CROSS SECTIONAL 
STUDY ON DIASTOLIC FUNCTION AND FACTORS INFLUENCING 
DIASTOLIC FUNCTION IN DIABETES MELLITUS PATIENTS 
WITH NORMAL SYSTOLIC FUNCTION” is a bonafide and genuine 
research work carried out by me at  GOVT. CHENGALPATTU MEDICAL 
COLLEGE AND HOSPITAL from June 2014 to June 2015 under the 
guidance and supervision of  Dr. V. R. MOHAN RAO M.D, Professor and 
H.O.D , Department of General Medicine, Chengalpattu Medical College, 
Chengalpattu – 603 001. 
 
Signature of Guide     Signature of the Candidate 
Department of General Medicine    (Dr. VENKATESWARI.S) 
Chengalpattu Medical College 
Chengalpattu.  
 
       
  
Professor and Head of Department 
Department of General Medicine 
Chengalpattu Medical College 
Chengalpattu. 
ACKNOWLEDGEMENT 
 
I would like to take this opportunity to express my deep sense of 
gratitude towards Dr. V. R. MOHAN RAO M.D, Professor and H.O.D, 
Department of General Medicine, Chengalpattu Medical College, 
Chengalpattu  for his valuable guidance, constant encouragement and expert 
suggestions, in spite of his busy schedule, which was most crucial in 
overcoming various difficulties. I will remain thankful for his guidance, 
inspiration and constant support. 
I would like to thank Dr. Ragothaman M. D., D.M (cardiology) for 
his guidance and generous support given during my study.   
I am indebted to Dr. N. Ravishankar M.D, Dr. B. Prabhakar M.D., 
Dr. G. Dharmaraj M.D., Dr. S. Abirami M.D., Assistant Professors of 
Medicine for their guidance and help given during my course and thesis work. 
I sincerely thank Dr. P. Parameshwari M.D, Dr. P. Getrude 
Banumathy M.D, Dr. D. Jai Ganesh M.D, Assistant Professors of 
department of Social and Preventive Medicine, Chengalpattu Medical College, 
Chengalpattu who helped me throughout my study in guided me in 
interpreting the results of my study. 
I am indebted to Dr .K. Muthuraj M.S, Dean, Chengalpattu Medical 
College for permitting me to carry out this study. 
I am extremely thankful to all my friends and colleagues for their 
untiring support.  
I would like to thank my parents who constantly encouraged me and 
moral support. 
Last but not least, I am grateful to all those patients who were the 
subjects for this study, without whose co-operation this work would not have 
been possible.  
I  bow my head in respect before God Almighty. 
 
 
Date:      Signature of the Candidate 
Place : Chengalpattu             Name : Dr.VENKATESWARI.S   
 
 
 
 
 
 
 
 
 
  



TABLE OF CONTENTS 
 
SL. NO CONTENTS PAGE. NO 
I INTRODUCTION 1 
II AIMS AND OBJECTIVES 3 
III REVIEW OF LITERATURE 
 
1. Metabolic abnormalities in Diabetes 
2. Diabetic Cardiomyopathy 
3. Etiology of diabetic cardiomyopathy 
4. Diastolic dysfunction 
5. Diastolic heart failure 
6. Pathophysiology of diastolic dysfunction 
in diabetes 
7. Obesity, dyslipidemia and diastolic 
dysfunction 
8. Smoking and diastolic dysfunction 
9. Age and diastolic dysfunction 
10. Echocardiography 
11. Management 
a. Screening 
b. Non pharmacological therapy 
c. Pharmacological therapy 
4 
IV 
METHODOLOGY 
37 
V  
RESULTS 
41 
VI 
DISCUSSION 
80 
VII 
CONCLUSION 
88 
VIII ANNEXURES (BIBLIOGRAPHY, 
PROFORMA, MASTER CHART) 
89 
LIST OF TABLES 
 
SL. NO CONTENTS PAGE. NO 
1 Showing age distribution 42 
2 Showing gender distribution  43 
3 Showing distribution of duration 44 
4 Showing occurrence of dyslipidemia 45 
5 Showing occurrence of obesity 46 
6 Showing occurrence of glycaemic control 47 
7 Showing occurrence of smoking 49 
8 Showing age wise distribution of diastolic 
dysfunction in diabetic patients 
51 
9 Showing age wise distribution of normal 
diastolic function in diabetic persons 
52 
10 Showing gender wise distribution of diastolic 
dysfunction  
56 
11 Showing gender wise distribution of normal  
diastolic function  
56 
         12 Showing correlation between diastolic 
dysfunction and glycaemic control 
60 
13 Showing correlation between normal diastolic 
function and glycaemic control 
61 
14 Showing correlation between diastolic 
dysfunction and duration of diabetes 
64 
15 Showing correlation between normal diastolic 
function and duration of diabetes 
65 
16 Showing correlation between diastolic 
dysfunction and smoking 
68 
17 Showing correlation between normal diastolic 
function and smoking 
68 
18 Showing correlation between diastolic 
dysfunction and dyslipidemia 
72 
19 Showing correlation between normal diastolic 
function and dyslipidemia 
72 
20 Showing correlation between diastolic 
dysfunction and obesity 
76 
21 Showing correlation between normal diastolic 
function and obesity 
76 
 
LIST OF GRAPHS 
 
SL. NO CONTENTS PAGE. NO 
1 Showing age distribution 42 
2 Showing gender distribution 43 
3 Showing distribution of duration 44 
4 Showing occurrence of dyslipdemia  
 
45 
5 Showing occurrence of obesity 46 
6 Showing occurrence of glycaemic control 48 
7 Showing occurrence of smoking 50 
8 Showing age wise distribution of diabetic 
persons 
53 
9  Showing distribution of normal diastolic 
function 
54 
10 Showing correlation of age and diastolic 
dysfunction in  diabetes 
55 
11 Distribution of diastolic dysfunction in males 57 
12 Distribution of diastolic dysfunction in female 58 
13 Showing correlation between gender and 
diastolic dysfunction 
59 
14 Showing diastolic dysfunction and glycaemic 
status 
 
61 
15 Showing normal diastolic function and 
glycaemic status 
62 
16 Showing correlation between diastolic 
dysfunction and glycaemic control 
63 
17 Showing diastolic function in cases with good 
glycaemic control 
63 
18 Showing diastolic function in cases with poor 
glycaemic control 
64 
19 Showing diastolic dysfunction and duration of 
diabetes 
65 
20 Showing normal diastolic function and duration 
of diabetes 
66 
21 Showing correlation between diastolic 
dysfunction and duration of diabetes 
67 
22 Showing diastolic dysfunction and smoking 69 
23 Showing normal diastolic function and smoking 69 
24 Showing correlation between diastolic 
dysfunction and smoking 
70 
25 Showing diastolic dysfunction in smokers 71 
26 Showing diastolic dysfunction in non smokers 71 
27 Showing diastolic dysfunction and dyslipidemia 73 
28 Showing normal diastolic function and 
dyslipidemia 
 
73 
29 Showing correlation with dyslipidemia 74 
30 Showing diastolic dysfunction in dyslipidemic 
cases 
75 
31 Showing diastolic dysfunction in cases with 
normal lipid profile 
75 
32 Showing diastolic dysfunction and obesity 77 
33 Showing normal diastolic function and obesity 77 
34 Showing correlation between diastolic 
dysfunction and obesity 
78 
35 Showing diastolic dysfunction in obese cases 79 
36 Showing diastolic dysfunction in non obese 
cases 
79 
 
 
 
 
 
LIST OF ABBREVIATIONS USED 
 
CHD Coronary Heart Disease 
CHF Congestive Heart Failure 
NYHA New York Heart Association 
EF Ejection Fraction 
NO Nitric Oxide 
NOS Nitric Oxide Synthase 
ROS Reactive Oxygen Species 
AGE Advanced Glycation End Products 
PKC Protein Kinase C 
MAP Mitogen Activated Protein 
ADMA Asymmetric Di Methyl Arginine 
HDL High Density Lipoprotein 
VLDL Very Low Density Lipoprotein 
LDL Low Density Lipoprotein 
NEFA Non Esterified Fatty Acids 
LV Left Ventricle 
LA Left Atrium 
ACE Angiotensin Converting Enzyme 
cms Centimeters 
 
 
  1 
 
INTRODUCTION 
 
The disease burden of diabetes mellitus is increasing worldwide at a 
tremendous rate and a country like India with second largest population 
worldwide is not an exception. 
Numerous studies have reported the increased occurrence of diastolic 
dysfunction in diabetic persons as a separate clinical entity and they have 
thrown light that the prevalence of heart failure in diabetic patients is high 
even in the absence of other risk factors like coronary artery disease and 
hypertension. 
It has been further insisted that the prevalence of preclinical  diastolic  
dysfunction is high as per the studies. Evidence available as of now suggests 
that diastolic dysfunction antedates systolic dysfunction in diabetic patients. 
The factors which are  proposed as responsible for diastolic dysfunction 
are multiple and consist of autonomic dysfunction, microvascular disease, 
interstitial fibrosis and metabolic disorders like associated obesity and 
dyslipidemia. Never the less the exact etiopathogenesis of diabetic 
cardiomyopathy remains unclear. 
Obesity is proved to be an independent risk factor for the incidence of 
heart failure in worldwide general  population. Also available evidence 
suggests that over weight also carries  risk of heart failure which lies 
intermediary between lean and obese patients. 
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The effects of obesity of longer duration on structure and function of 
left ventricle can be in the form of  Left Ventricular hypertrophy of eccentric 
type, defective diastolic function and sometimes  systolic dysfunction. Till 
date, the effects of obesity on the function and structure of cardiovascular 
system remains a subject of debate. 
Smoking has negative effects  almost all systems in our body, the main 
brunt of  injury is taken by the cardiovascular and respiratory systems. In 
cardiovascular system, smoking affects both endothelial and cardiac structure 
and performance, both of which are interlinked. 
Till date only few population based studies have been performed in our 
country to detect and evaluate the presence of diastolic dysfunction in diabetic 
patients and to quantify the relation between glycemic control, duration of 
diabetes, and coexisting and independent risk factors and their negative 
affection of cardiac performance. 
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AIMS AND OBJECTIVES 
 
x To determine the prevalence of Left ventricular diastolic dysfunction in   
Type- 2 Diabetes mellitus patients with no symptoms 
x To quantify the relation between Left Ventricular diastolic dysfunction 
and  
o Age 
o Gender 
o  Duration of Diabetes 
o Control of Diabetes 
o  Smoking 
o Dyslipidemia and  
o Obesity  
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REVIEW OF LITERATURE 
 
            The term diabetes mellitus describes a metabolic cum vascular 
syndrome of various etiologies which is characterized by hyperglycemia along 
with disturbances of metabolism of carbohydrate, protein and fat which can be 
due to either defective insulin secretion or defective insulin action or both 
resulting in changes in both small blood vessels (microangiopathy) and large 
caliber blood vessels (macroangiopathy). 
This definition is useful in that it conveys a sense of the etiology, 
pathogenesis, biochemical features and implications in diabetes mellitus. 
Diabetes mellitus is the most common metabolic disorder in the world. 
According to the data available as of now around 387 million in the world live 
with diabetes.  
In most of the nations the number of patients with diabetes is increasing 
steadily. Largest number of people with diabetes are present in China (98 
million) followed by India (65 million). 
In India the prevalence rates of diabetes have increased tremendously 
since the time the initial national survey was done. The reason for this 
explosive increase in the case burden of diabetes in India has been the subject 
of interest. While a high level of genetic predisposition does plays a role, it is 
unlikely that the genetic makeup of the population has drastically changed in 
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the past thirty years as to account for the tremendous increase in the case 
burden of diabetes. 
 More likely explanation is that the increasing urbanization and 
prosperity have led to wholesale changes in the lifestyle of our population 
which cause diabetes to manifest in the individuals who have a genetic 
predisposition.   
METABOLIC ABNORMALITIES IN DIABETES: 
Type 2 diabetes represents a continuum of clinical scenarios, ranging 
from severe resistance to insulin along with relative insulin deficiency to 
severe insulin deficiency accompanied by some degrees of insulin resistance. 
Both insulin resistance and insulin deficiency are essential for diabetes to-
develop. A person with severe insulin resistance will not develop diabetes 
unless his secretion of insulin drops below a critical threshold. But the 
converse is true and this scenario leads to type 1 diabetes mellitus. 
Till now it is not very clear regarding which comes first – insulin 
resistance or insulin secretary defect. All persons become insulin resistant to 
some extent as they grow older.  
However, most of the individuals have sufficient beta cell reserve to 
overcome this metabolic resistance and prevent3 the development of type 2 
diabetes. It might be that individuals who develop type 2 diabetes have a 
decreased beta cell reserve, which renders them incapable of overcoming 
insulin resistance over a period of time. 
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Insulin resistance can be inherited or acquired. The most important 
corollary of insulin resistance is obesity, particularly abdominal type of 
obesity, which again can occur due to genetic or environmental factors. There 
are certain genetic syndromes of severe resistance to insulin, most of which 
are associated with diabetes. Reversible causes of resistance to insulin include 
chronic hyperglycaemia otherwise called as glucotoxicity and physical 
inactivity.  
Resistance to insulin can occur at the level of the insulin receptor or in 
the post receptor pathways. Down regulation of the receptors as well as anti 
insulin and anti insulin receptor antibodies have been implicated in the 
etiopathogenesis of diabetes.  
It is of interest that the resistance seems to develop only to the 
metabolic effects of insulin which are mediated by the P13K pathway but not 
to the mitogenic effects which are mediated by the Grb-SOS pathway. 
The major contributor to the beta cell dysfunction is genetic. The genes 
which are responsible for this impairment in beta cell function are unknown. 
The beta cell defect is progressive and can be detected even in individuals 
those who have impaired glucose tolerance.  
On an average, persons would have lost about half of their insulin 
reserve by the time they develop diabetes. Environmental factors that 
contribute to beta cell dysfunction include increased free fatty acids 
(lipotoxicity), chronic hyperglycemia (glucotoxicity), alterations in the 
incretin axis, and in utero malnutrition. Rather than a structural defect, a 
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functional defect seems to be responsible for the beta cell dysfunction in 
diabetes.  
Of late, in addition to the pathophysiologic defects discussed till now, 
other organs have also been postulated to play a role in the pathogenesis of 
type 2 diabetes. The comprehensive model incorporating all these varying 
pathophysiologies has been termed as the ominous octet.  
Though diabetes affects multiple organ systems cardiovascular disease 
caused and complicated by diabetes is one of the leading causes of mortality 
and morbidity in diabetic patients and is discussed in detail below. 
DIABETIC CARDIOMYOPATHY: 
Diabetic cardiomyopathy is a term used by clinicians to encompass the 
multi factorial etiologies of diabetes related left ventricular failure 
characterized by both systolic and diastolic function.48 The Framingham Heart 
Study showed that men with diabetes who have congestive heart failure were 
twice as common as their non diabetic counterpart, and that females with 
diabetes had a fivefold increase, in the rate of congestive heart failure.  
This spectrum ranges from asymptomatic to overt systolic failure. 
Diabetes complicated by hypertension represents a particularly high risk group 
for the development of congestive heart failure.49 Diastolic dysfunction is 
exceedingly common (>50 percent prevalence in some studies) and may be 
linked to diabetes without the presence of concomitant hypertension. 
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ETIOLOGY: 
The etiology of impaired left ventricular function may involve any of 
the following mechanisms:  
1) Coronary atherosclerotic disease, 
2) Hypertension, 
3) Left ventricular hypertrophy, 
4) Obesity,  
5) Endothelial dysfunction,  
6) Coronary microvasculature disease,  
7) Autonomic dysfunction, and  
8) Metabolic abnormalities. 
Both diabetes and cardiovascular communities have embraced the 
concept of diabetic cardiomyopathy as a distinct entity independent of 
ischemic heart disease and hypertension. This was first described in the early 
1970s when autopsy specimens of diabetic patients with nephropathy 
demonstrated a myopathic process in the absence of epicardial CHD. 
It has been further insisted that there is high prevalence of preclinical 
diastolic dysfunction as per the studies that have been conducted so far. 
Evidence available as of now suggests that diastolic dysfunction precedes 
systolic dysfunction in diabetic patients. 
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 As discussed above, the cardiovascular performance in a patient with 
diabetes mellitus is affected by various conditions like diabetic 
cardiomyopathy, coronary artery atherosclerosis, or autonomic neuropathy. 
In a patient with diabetes mellitus poor cardiac performance may be 
due to predominantly any of these conditions or due to their combined effect. 
There is steadily growing idea which is being recognised that congestive heart 
failure (CHF) caused mainly by a defect in diastolic function (ie, diastolic 
heart failure) is quite common and might cause significant morbidity and 
mortality in persons having type 2 diabetes.  However, the definition of 
diastolic dysfunction and  the criteria for diagnosing diastolic heart failure 
have not been explained clearly.  
DIASTOLIC DYSFUNCTION: 
Diastolic dysfunction can be described as a condition where 
abnormalities in mechanical function of the cardiac musculature are present 
during diastole. Abnormal diastolic cardiac performance might be present 
along with or without a clinical syndrome of heart failure. Also, defective 
diastolic function of the cardiac musculature can occur in combination with 
normal or abnormal systolic function.  
Conceptually, diastole consists of the time period during which the 
myocardium loses its ability to generate force and shorten and returns to an 
un-stressed length and force. So keeping this in mind we could say, diastolic 
dysfunction occurs when these processes are being slowed, incomplete or 
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prolonged. Whether this time period is best described by classic concepts and 
parameters or the newly proposed ones is under evaluation. 
The measurements which might reflect changes in the normal diastolic 
function in general depend on factors like rate, onset, and extent of fall in 
ventricular pressure and filling and the relationship between strain and stress 
or in other words volume or pressure happening during the period of diastole. 
Moreover, if diastolic function is truly normal, these measurements must 
remain normal both at rest and during the stress, of a variable heart rate, stroke 
volume, blood pressure and end diastolic volume.  
DIASTOLIC HEART FAILURE: 
Diastolic heart failure is a clinical syndrome which comprises of 
symptoms and signs of heart failure along with abnormal diastolic 
performance and a preserved ejection fraction as assessed by appropriate 
parameters. 
From a conceptual point of view, diastolic heart failure occurs when 
there is inability of ventricular chamber for acceptance of a sufficient volume 
of blood during diastole, at normal diastolic pressures and at volumes which 
are adequate to maintain an appropriate stroke volume.   
These abnormalities are caused by a fall in relaxation of ventricular 
chamber and/or an increase in stiffness of ventricle. Diastolic heart failure can 
produce symptoms that occur at rest (New York Heart Association [NYHA] 
class IV), symptoms that occur with less than ordinary Physical activity 
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(NYHA class-III), or symptoms that occur with ordinary physical activity 
(NYHA class II). 
Therefore, whereas diastolic dysfunction describes an abnormal 
mechanical property, diastolic heart failure describes a clinical syndrome. 
Diastolic heart failure can occur singly or along with systolic heart 
failure. In persons having isolated diastolic heart failure, major abnormality in 
the pressure-volume relationship occurs during diastole, when increased 
diastolic pressures accompany normal diastolic volumes. Ultimately diastolic 
pressure gets elevated markedly and persons become symptomatic even at rest 
or with minimal physical activity (NYHA class III to IV).  
Appropriate treatment may lead to fall in diastolic volume and pressure, 
and the individual becomes less symptomatic (NYHA class II), even then 
diastolic pressure-volume relationship continues to be abnormal. In patients 
with systolic heart failure, abnormalities occur in the pressure-volume 
relationship during systole and these comprise of fall in EF, stroke volume, 
and stroke work. Changes in the diastolic portion of the pressure-volume 
relationship accompany these. 
All the above discussed changes lead to rise in diastolic pressures in 
symptomatic persons, thus indicating presence of both systolic and diastolic 
heart failure. Whereas the diastolic pressure-volume relationship may reflect a 
more compliant chamber, increased diastolic pressure and abnormal relaxation 
reflect the presence of abnormal diastolic function. Thus, all patients with 
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systolic heart failure and elevated diastolic pressures actually have combined 
systolic and diastolic heart failure. 
Another form of heart failure as combined systolic and diastolic heart 
failure is also possible. Patients may have only a modest decrease in EF and a 
modest increase in end diastolic volume but a marked increase in end diastolic 
pressure and a diastolic pressure-volume relationship that reflects decreased 
chamber compliance. Therefore, virtually all patients with symptomatic heart 
failure have abnormalities in diastolic function, those with a normal EF have 
isolated diastolic heart failure, and those with a decreased EF have combined 
systolic and diastolic heart failure. 
PATHOPHYSIOLOGY OF DIASTOLIC DYSFUNCTION IN 
DIABETES: 
Diastolic phase of cardiac cycle can be discussed in four different 
phases and they are as follows: 
1) Isovolumetric relaxation 
2) Early diastolic filling, i.e. rapid filling 
3) Diastasis  
4) Late diastolic filling, i.e. atrial contraction. 
Two aspects of diastolic function namely relaxation and stiffness is 
usually discussed together, but in reality they describe different properties of 
cardiac musculature. Relaxation is an active myocardial process which 
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consumes energy. This phase begins at the end of contraction and continues as 
long as isovolumetric relaxation and early diastolic filling occurs. Defective 
relaxation is one which is either delayed or partial and can be the result of 
regional dyssynchrony or fall in energy supply, as in myocardial ischemia or 
hypertrophy.  
Diastolic stiffness can be estimated at the end of diastole after filling 
has completed and is calculated from curvilinear pressure–volume 
relationship. The slope of the tangent (dP/dv) of this relationship describes the 
stiffness of chamber at any given filling pressure. Changes in stiffness can be 
the result of differences in the composition and material properties of the 
cardiac musculature, such as interstitial fibrosis and left ventricular 
hypertrophy or both. In both metabolic syndrome and diabetes mellitus, 
diastolic dysfunction results from abnormal myocardial active relaxation and 
an increase in passive stiffness due to metabolic derangements and structural 
remodeling. 
In a normal myocardium, phase of early diastolic filling which lasts 
roughly for hundred milliseconds extracts around 80 % of total filling volume 
by an energy driven active process of extension of cardiac musculature.    
Diabetes causes metabolic abnormalities, including hyperglycemia, 
dyslipidemia, and insulin resistance, increased free fatty acid concentrations 
that alter normal arterial function and make arteries prone for atherosclerosis. 
It specifically alters the function of vascular endothelium and smooth muscle 
cells, as well as platelets, in ways that promote atherogenesis. Also diabetes 
disrupts the vasodilator function of endothelial cells and decreases the 
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bioavailability of nitric oxide (NO) by which it accelerates diastolic 
dysfunction.  
Endothelial dysfunction also occurs in healthy adult offspring of type 2 
diabetic parents, suggesting an inheritable abnormality as well. 
Hyperglycemia decreases NO production from endothelial nitric oxide 
synthase (eNOS) and increases its degradation via generation of reactive 
oxygen species (ROS). Hyperglycemia triggers the production of ROS in 
vascular cells through enzymatic (protein kinase C and the reduced form of 
nicotinamide adenine dinucleotide phosphate [NADPH] oxidases and non 
enzymatic sources of oxidant stress (e.g., the formation of advanced glycation 
end products, AGEs). As oxidative stress increases, the eNOS cofactor 
tetrahydrobiopterin becomes oxidized and uncouples eNOS, which cause the 
enzyme to produce superoxide anion instead of NO. Superoxide anion 
quenches NO in a diffusion limited reaction to produce peroxynitrite.  
Peroxynitrite inhibits prostacyclin synthase and endothelium-dependent 
hyperpolarizing factor activity. Similar to the effects of hyperglycemia, free 
fatty acids activate intracellular enzymatic oxidant sources, including protein 
kinase C, NADPH oxidases, and eNOS, yielding analogous increases in 
superoxide anion. 
Diabetes impairs vascular smooth muscle function and augments the 
production of vasoconstrictor mediators, including endothelin-,1[1] which 
causes vascular smooth muscle growth and inflammation. Levels of other 
atherogenic mediators, including angiotensin II and vasoconstrictor 
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prostanoids, increase in diabetes as well.[1] Patients with type 2 diabetes have 
impaired vasodilation, possibly reflecting an abnormality in NO signal 
transduction.[26] 
Moreover, diabetic patients have attenuated vasoconstriction to 
endothelin-1 and angiotensin.[54] Diabetes may alter sub cellular calcium 
distribution in smooth muscle cells,[55] resulting in augmented vasoconstriction 
in response to norepinephrine and phenylephrine. However, most diabetics 
have peripheral autonomic impairment at the time of diagnosis, and vascular 
beds regulated by these nerves have decreased arterial resistance.[1]  
Similar to endothelial cells, diabetes activates atherogenic mechanisms 
within vascular smooth muscle cells, including protein kinase C, RAGE, NF-
kB and the production of oxidative stress.[30] Diabetes heightens vascular 
smooth muscle cell migration in atherosclerotic lesions. Advanced 
atherosclerotic lesions have fewer vascular smooth muscle cells in diabetic 
patients than non diabetic patients, possibly resulting in decreased resiliency 
of the fibrous cap and thereby increasing the risk of rupture and luminal 
thrombosis.[56] 
Other contributing agents believed to aid in the development of diabetic 
myocardial dysfunction is discussed in detail below. The clustering of 
cardiovascular risk factors in the diabetic persons induces multiple complex 
metabolic reactions, most prominent among which are  
 Altered insulin signaling  
 Glucotoxicity  
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 Lipotoxicity    
 Elevated activity of cytokines   
 Intramyocyte and interstitial triacyl glycerol deposition   
 Advanced Glycation End products accumulation 
All these may affect the functioning of the myocardium either directly 
or indirectly. In addition, all the above said risk factors trigger the endothelial 
dysfunction in a additive fashion.  
Among the end results of progressive endothelial dysfunction are 
dysregulation of vascular permeability, inflammatory responses and 
predominantly vascular remodelling and atherosclerosis affecting coronary 
and systemic arteries. This response is mediated by rise in tone of vessels and 
associated with subsequent rise in arterial stiffness, blood pressure and pulse 
pressure. The resultant rise in after load in the vascular system compels heart 
to work in an elevated level of resting myocardial oxygen consumption. 
However, this increased demand of energy leads to less favourable 
down regulation of perfusion of cardiac musculature, impaired intracellular 
bioenergetics and decreased efficiency. This situation may be considered an 
energy demand/supply mismatch based on abnormalities caused by 
metabolism inducing stress in cardiomyocytes. Subsequently, myocardial 
hypertrophy, autonomic dysfunction and left ventricular diastolic dysfunction 
may develop, characterizing the first stage of diabetic cardiomyopathy. This 
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stage may remain without manifesting symptoms for a quite long period and 
antedates the onset of systolic dysfunction. 
In the advanced stages of diabetes, diastolic dysfunction may increase 
further due to cumulative structural abnormalities of cardiac musculature, such 
as steatosis cardialis, Advanced Glycation End product deposits, interstitial 
fibrosis and alterations in the extracellular matrix microvasculature which 
characterize the advanced stages of diabetic cardiomyopathy. 
Early diastolic function depends on both stiffness of cardiac 
musculature and availability of energy for utilization. For years together, the 
pathophysiological mechanisms of defective filling of left ventricle were 
attributed to elevated myocardial stiffness due to structural changes in the 
myocardium. Myocardial stiffness mainly has an impact on late phase of 
diastolic function but may also affect relaxation properties. A recent study 
based on left ventricular endomyocardial biopsy samples showed that systolic 
heart failure in diabetic patients was due to increased myocardial stiffness 
caused by advanced glycation end products deposition and fibrosis.  
But in reality, the major contributors to diastolic dysfunction are high 
resting tension and hypertrophy of cardiac myocytes. Of interest, hypertrophy 
of cardiac musculature in diabetes was unrelated to pressure overload instead 
to increased fasting levels of insulin, stating insulin resistance as a contributor 
to hypertrophy of cardiac myocytes. In addition to stiffness, there is also a 
reversible dynamic component which was based on the fact that early diastolic 
relaxation and filling are energy-consuming, active processes.  
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Two greatly accepted examples of this dynamic component are the 
immediate and reversible nature of diastolic dysfunction during stress testing 
and during coronary arterial balloon inflation, and, this may be regarded as an 
iatrogenic model of regional and intermittent impairment of myocardial 
energy supply in human beings. This model, with an exact onset and offset of 
perfusion blockade, has confirmed the increased susceptibility of myocardial 
diastolic function to energy derangements by the occurrence of diastolic 
dysfunction, not only before but also extending far beyond systolic 
dysfunction. Limitations in energy supply may arise not only, from 
deficiencies in circulatory transport and perfusion but also from the 
intracellular processes involved in biochemical energy production and 
substrate utilization. 
Alterations in metabolism which result in decreased resource of energy 
are discussed as follows. Altered insulin signaling and elevated reactive 
oxygen species production have recently been proved in individuals with 
uncomplicated type 2 diabetes. 
The widely proposed mechanism of action of reactive oxygen species 
involves the regulation of energy availability. Indirect effects may include 
decreased perfusion due to induction of endothelial dysfunction. Direct effects 
on cardiomyocytes cause resultant altered energy production in 
mitochondrium by disrupted supply of substrate and its utilization and 
mitochondrial uncoupling, the net result of which is decreased cardiac 
efficiency and altered insulin signaling. 
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The latter plays a key role in insulin resistance, decreased bio-
availability of nitric oxide, altered handling of calcium and mitochondrial 
damage and dysfunction, finally resulting in abnormal cardiac remodeling and 
ventricular dysfunction. Acknowledging diastolic dysfunction as an indicator 
of reduced myocardial energy availability would provide a better 
understanding of why augmentation may be observed with short-term 
improvement of glycaemic control in type 2 diabetes and acute increase in 
perfusion of myocardium by administering C peptide in young and athletic 
individuals who have type 1 diabetes. 
There is an increasing number of reports which show that the extent of 
hyperglycaemia correlates with diabetic myocardial dysfunction, and good 
control of blood sugar level decreases the risk of heart failure. These studies 
further infer that the improvement in diastolic function correlates with the 
extent of improved blood sugar control. The optimal glucose-lowering 
regimen which can aid in the protection of diabetic individuals from diastolic 
heart failure await to be determined in future research. 
Rapid filling of the left ventricle has been shown to be a sensitive 
indicator of all types of myocardial damage [34], being susceptible not only to 
age and ischaemia but also to virtually all cardiovascular risk factors, which 
includes the metabolic syndrome and diabetes mellitus. In acceptance with the 
above said findings is the reversibility of impaired diastolic function, as 
demonstrated by effective treatment of any of these risk factors, including a 
sedentary lifestyle and obesity[23]. Notably, this reversible component of  
altered myocardial function associated with the metabolic syndrome and 
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diabetes is welcome news for diabetic individuals and their treating doctors 
and is in accordance with the message from the UK Prospective Diabetes 
follow-up study, that the most effective treatment is started early in the course 
of the disease. 
OBESITY, DYSLIPIDEMIA AND DIASTOLIC DYSFUNCTION: 
The excess adipose tissue that usually accompanies type 2 diabetes 
mellitus releases excess fatty acids. Reduced skeletal muscle uptake of free 
fatty acids further augments their plasma levels.[32] Increased concentrations of 
free fatty acids exert deleterious actions in several areas. In healthy humans, 
free fatty acid infusion impairs endothelial function and the co-infusion of an 
antioxidant restores it.[33] Free fatty acids also attenuate prostacyclin 
bioavailability by inhibiting prostacyclin synthase.[34] Moreover, free fatty 
acids interfere with intracellular signaling pathways to cause not only muscle 
and visceral insulin resistance but also vascular insulin resistance.[35] 
In diabetes, hyperglycemia and increased free fatty acids increase the 
concentration in the cell of the metabolite diacylglycerol.[36] Diacylglycerol, in 
turn, activates a family of enzymes known as protein kinase C (PK-C), that 
perform key regulatory functions by phosphorylating proteins important in 
metabolic control. Recent work[30] has implicated activation of the PKC family 
in cardiovascular complications of diabetes. Activation of PKC can inhibit the 
expression of eNOS, augment cytokine-induced tissue factor gene expression 
and pro coagulant activity in human endothelial cells, and increase the 
production of pro inflammatory cytokines, proliferation of vascular wall cells, 
and production of extracellular matrix macromolecules that accumulate during 
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atherosclerotic lesion formation.[30] In vivo evidence has supported a role of 
PK-C activation in the pathogenesis of various aspects of vascular dysfunction 
in vivo. Administration of a selective inhibitor of protein kinase C-beta (PKC-
b) prevents impaired endothelial function in healthy humans exposed to 
hyperglycemia, reduces visual loss in diabetic patients with retinopathy, and 
may attenuate diabetic neuropathy .[37] [38] [39] 
Although typically associated with impairments in skeletal glucose 
muscle uptake, many tissues in the diabetic patient demonstrate insulin 
resistance, including adipose, liver, and endothelial cells.[27] Normal vascular 
function requires intact endothelial insulin signaling. For example, in 
genetically engineered mice that lack the endothelial cell insulin receptor, 
vascular endothelial nitric oxide synthase concentration decreases 60 
percent.[40] Endothelial insulin resistance alters the pattern of activation of 
intracellular signaling pathways, favoring stimulation of mitogen-activated 
protein (MAP) kinases over phosphatidylinositol 3 (PI-3) kinase. Preferential 
activation of the MAP kinase pathway decreases nitric oxide production, 
increases endothelin production, stimulates the transcription of inflammatory 
genes, and increases the tendency to coagulation.[41] Drug-induced 
improvement in insulin sensitivity reduces cytokine production and 
inflammatory transcription factor activation and increases nitric oxide 
bioavailability. [42] [43] 
Studies have now identified a new potential mechanism for mediating 
the already damaged endothelial-dependent vasodilator function. An 
endogenous competitive inhibitor of nitric oxide synthase, which is named as 
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asymmetric dimethyl arginine (ADMA), increases directly with insulin 
resistance in non diabetic subjects and glycemic control in diabetes[44] and 
improves with glycemic control.[45] The accumulation of ADMA may result 
from inhibition of its degradation because of reduction in activity of the 
enzyme dimethyl arginine dimethyl amino hydrolase. Another study has 
suggested that dys regulation of this enzyme raises levels of ADMA in 
diabetics.[46] These findings indicate another potential molecular pathway of 
impaired[90] vascular function in diabetes. 
Adipocytes can also elaborate chemo attractant molecules, such as 
monocyte chemo attractant protein, which can recruit inflammatory leukocytes 
to enter adipose tissue.[24] Once present, these “professional” phagocytes can 
amplify the production of pro inflammatory mediators and perpetuate the 
inflammatory cycle related to insulin resistance and the vascular complications 
of diabetes mellitus. Some evidence has suggested that visceral adipose tissue 
plays a particularly pernicious role in perpetuating pro inflammatory pathways 
by producing proportionately more of these mediators than subcutaneous 
adipose tissue.[25] Waist circumference and visceral adiposity, as determined 
by imaging, correlate with C-reactive protein levels, indicating a relationship 
between inflammatory burden and central obesity. Moreover, liposuction, 
which evacuates subcutaneous but not visceral fat stores, does not lower C-
reactive protein levels, whereas weight loss produced by restricted caloric 
intake or increased physical activity does diminish levels of this inflammatory 
marker. Thus, as with many other pro atherosclerotic risk factors, adiposity 
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can promote inflammation and potentiate the vascular disease associated with 
diabetes and its complications.[25] 
Defective action of insulin in the liver leads to inappropriate release of 
glucose, leading to fasting hyperglycemia. Usually, the glucose production 
from liver is completely suppressed after a meal, mainly due to action of 
insulin. This suppression does not occur in diabetic persons with resistance to 
insulin thus resulting in postprandial hyperglycemia. Also, the production and 
release of very low density lipoprotein (VLDL) is stimulated, which 
contributes to hypertriglyceridemia. Diabetic patients with 
hypertriglyceridemia tend to have low levels of high density lipoprotein 
(HDL) in their circulation, possibly because of exchange of triglycerides and 
cholesterol esters between high density lipoprotein and triglyceride repletes 
proteins like very low density lipoprotein, rendering HDL particles more 
susceptible to degradation. 
Also, the higher levels of very low density lipoprotein lead to increased 
exchange of cholesterol ester and triglyceride between very low density 
lipoprotein and low density lipoprotein (LDL) thus raising the triglyceride 
content of low density lipoprotein and rendering them more vulnerable to de-
gradation by hepatic lipase. The resultant process is the formation of small 
dense LDL particles.  
The lipid profile in a diabetic person is described by elevated 
triglyceride levels, low high density lipoprotein cholesterol levels and normal 
to high normal levels of low density lipoprotein cholesterol levels. There is a 
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relative rise in number of atherogenic small dense LDL particles. All this 
comprises of what is termed as “Diabetic Dyslipidemia”.  
Defective insulin action in adipose tissue results in excessive break 
down of triglycerides and formation of non esterified fatty acids (NEFA), high 
levels of which can reduce insulin stimulated uptake of glucose by the tissues 
and can stimulate gluconeogenesis in the liver. Although lipolysis is increased, 
over-production of ketone bodies does not occur in type 2 diabetes because the 
deficiency of insulin is not absolute; smaller amounts of insulin are sufficient 
to prevent ketogenesis than to maintain glucose homeostasis. 
SMOKING AND DIASTOLIC DYSFUNCTION: 
Smoking has numerous adverse effects on various organ systems, but 
the most adversely affected ones are the respiratory and circulatory systems. In 
addition to other well documented harmful effects, smoking has been reported 
to have adverse effects on the diastolic function of the heart. Numerous prior 
studies have mainly focused on the acutely caused changes of smoking on 
diastolic function in different groups. 
There are possible explanations for the chronic adverse effects of 
smoking on the diastolic function of the heart, as demonstrated in the present 
study. Smoking has long been known to impair the structure of connective 
tissue in various organ systems. Increased arterial stiffness in smokers has 
been linked to structural alterations in the vascular media, including 
calcification [16], increased collagen and reduced elastin content [17]. 
Regardless of the presence of atherosclerosis, arterial and myocardial stiffness 
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have been clinically important in smokers. In canine models exposed to 
nicotine, increased LV chamber stiffness was reported to be due to increased 
collagen deposition and collagen cross-links in the myocardium [18]. Fibrotic 
changes throughout the myocardium due to collagen deposition may impair 
diastolic function in smokers. 
Impaired regulation of nitric oxide (NO) synthesis in the myocardium 
may be another possible mechanism explaining the impairment of relaxation 
in smokers. NO is synthesized via nitric oxide synthase (NOS). There are three 
known isoforms of NOS (NOS1, NOS2 and NOS3). Of these, NOS-2 and 
NOS-3[87] are known to be expressed in the human myocardium. NOS2 is an 
inducible isoform, and is not normally expressed, whereas NOS3 is 
endothelial and is physiologically expressed in the normal myocardium. The 
amount of NO synthesized via NO3 is generally much lower. The lower 
physiological amount of NO has some beneficial effects, including, an 
improvement in remodeling after myocardial infarction [19] and amelioration 
of ventricular relaxation (lusiotrophy). Smoking is a well- known factor that 
induces endothelial dysfunction through impairment of NO production [20, 
21]. Smoking may also impair ventricular relaxation by inhibiting 
physiological expression of NO3 in the myocardium.  
There may be clinical outcomes of asymptomatic diastolic dysfunction. 
The presence of diastolic dysfunction in an asymptomatic patient has been 
reported as a risk factor for the future development of heart failure [22]. In 
other terms, asymptomatic diastolic dysfunction might be an early marker of 
an increased risk of symptomatic heart failure and consequent mortality. 
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Persons with diastolic dysfunction are also considered to be susceptible to 
ventricular arrhythmias [23] and sudden cardiac death. An increased risk of 
arrhythmogenesis in diastolic dysfunction may be due to myocardial fibrosis, 
increased sympathetic tone, changes  in ex- citation-contraction coupling [23] 
and also to the minimal pathological changes in coronary microcirculation that 
do not induce documentable ischaemic changes [24] . 
AGE AND DIASTOLIC DYSFUNCTION: 
Diastolic function is partly dependent on age and this property 
differentiates normal function from dysfunction. Tissue Doppler imaging can 
be used to measure myocardial velocity parameters clearly show the 
predominant influence of age factor on diastolic function, which confirms 
previous reports using various imaging modalities. There is a steep and linear 
decline of normal early diastolic velocity with ageing in normal people, from 
16 cm/s at the age of 20 years to 6 cm/s at 80 years. This decline equals a 
decrease of 0.16 cm/s (i.e. 1% of the original value) every year.  So, cutoff 
values for normality vs dysfunction must be described as a linear regression 
equation as a function of age [19]. Using pulsed tissue Doppler imaging, the 
cut-off level for normal age-related velocity is calculated as 0.15 × age (years) 
+ 18(cm/s). This approach allows individual patients to be assigned to 
normality or dysfunction or risk and avoids the inconsistencies arising from 
normal values defined for different groups of age.  
 
 
  27 
 
ECHOCARDIOGRAPHY: 
Evaluating for diastolic dysfunction has always posed a challenge to 
echocardiography as the parameters assessed for the same should be easily 
applicable, acceptable and reproducible. Various studies have been conducted 
taking various echocardiographic parameters into account for finding, 
assessing and grading diastolic dysfunction. Though majority of the studies 
highlighted certain parameters like left ventricular mass, diastolic filling and 
mid wall systolic mechanics as potential parameters for study, they have been 
generalized and widely accepted after the advent of Doppler techniques which 
greatly complement echocardiography in identification, categorization and 
quantification of cardiac flow reserve and diastolic dysfunction 
Although the Left Ventricular end-diastolic pressure-volume relation is 
believed to de- scribe the passive properties of the LV, but, in reality LV 
filling is not a passive or slow process3. Actually, the peak flow rate across the 
mitral valve is either same or higher than the peak flow rate across the aortic 
valve. For correct interpretation of left ventricular filling dynamics derived 
from a wholesome echocardiographic evaluation, one should have an 
understanding of the physiological basis of LV filling. During LV ejection, 
energy is stored as the myocytes are compressed and the elastic elements in 
the myocardial wall are also twisted and compressed4. Relaxation of already 
contracted myocardium allows the stored energy to be released as the elastic 
elements recoil. This process leads to rapid fall in Left ventricular pressure 
during isovolumetric relaxation. All the more, during the initial 30 to 40 
milliseconds after opening of mitral valve, the ventricular wall tension gets 
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relaxed and this process is normally rapid enough to cause the LV pressure to 
continue to fall in spite of increase in LV volume5. 
This fall in ventricular pressure produces an early diastolic pressure 
gradient from the LA that extends to the LV apex. This accelerates blood out 
of the left atrium and produces rapid early diastolic flow that quickly 
propagates to the apex. Because the diastolic intraventricular pressure gradient 
pulls blood to the apex, it can be considered a measure of LV suction. It is 
found that this component of suction is decreased in experimental models of 
various conditions like heart failure, patients with ischemia, and hypertrophic 
cardiomyopathy10. The pressure gradient between LA and LV apex decides 
the rate of early filling of ventricle. Peak filling and peak pressure gradient are 
interlinked. Due to this close link peak filling occurs after the peak pressure 
gradient. The reduction in the early diastolic LV pressure will increase the 
gradient for filling and this will permit the heart to fill without requiring 
elevated LA pressure. Also, the ability to decrease LV early diastolic pressure 
in response to stress allows an increase in LV stroke volume without much 
increase in LA pressure.7 
The relaxing property of left ventricle is highly sensitive to myocardial 
dysfunction, and the ability to increase LV filling without an increase in LA 
pressure is reduced or absent in heart failure. Once the filling of left ventricle 
has started, the pressure gradient from LA to the LV apex falls and then 
reverses for short lived period. The reversed mitral valve pressure gradient 
decelerates and then stops the rapid flow of blood into the LV early in 
diastole. The time for flow deceleration is determined predominantly by the 
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functional LV chamber stiffness and provides a noninvasive indication of LV 
diastolic operating stiffness[13] During diastasis that is the midportion of 
diastole,  there is equalization of  pressure between LA and LV resulting in 
near cessation of mitral flow. During late phase of diastole, contraction of 
atrium produces a second LA- to-LV pressure gradient which aids again in the 
propulsion blood into the LV.  
Once the systolic phase of atrium is finished, atrium relaxes causing its 
pressure to fall below LV pressure, which results in beginning of closure of 
mitral valve. The onset of ventricular systole produces a rapid increase in LV 
pressure that seals the mitral valve and thus the diastole is ended.  
The dynamics of LV filling and their alteration with diastolic 
dysfunction are noninvasively assessed from Doppler measurement of mitral 
inflow velocity and tissue Doppler assessment of mitral annular velocity. 
Under normal circumstances, the peak early mitral inflow velocity (E) 
substantially exceeds the peak velocity during atrial contraction (A). Thus, the 
E/A ratio is 1. 
Because the LV apex remains unchanged throughout the cardiac cycle, 
the mitral annular velocity provides a useful measure of rate of long-axis 
lengthening. Under normal conditions, peak early diastolic mitral annular 
velocity which has also been called Ea, E and EM) occurs coincidentally with 
the mitral E (16,17). This is a manifestation of the symmetrical expansion of 
the LV in early diastole as blood moves rapidly to the LV apex in response to 
a progressive pressure gradient from the left atrium to the LV apex. 
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Under normal circumstances, both E and e respond to changes in the 
LA-to-LV pressure gradient. For example, both E and e normally increase in 
response to volume load and exercise 17–19 In the presence of mild diastolic 
dysfunction with slow LV relaxation but without an increase in LA pressure, 
the early diastolic pressure gradient that accelerates flow is decreased as a 
result of a higher LV pressure .20  
This results in a decrease in both the E and e and an increase in the 
importance of atrial contraction, producing an E/A ratio 1. The delayed 
relaxation results in a prolongation of E-wave deceleration time (DT) and may 
be associated with a mid diastolic peak of mitral flow (L wave).[21,22] With 
increased flow from the LA to LV with atrial contraction, the LA is relatively 
empty at the beginning of systole, which results in increased systolic velocities 
in the pulmonary veins toward the LA. This filling pattern has been called an 
impaired relaxation pattern or grade 1 diastolic dysfunction.[1,23] 
In most patients with this pattern, the mean LA pressure is not elevated 
despite an increased LV end diastolic pressure that is maintained by a vigorous 
atrial contraction.  
With progressive worsening of diastolic dysfunction associated with an 
increase in LA pressure, the early diastolic pressure gradient is restored 
despite increased diastolic LV pressures, resulting in a return of the E wave to 
the normal range pseudo normal mitral inflow pattern or grade 2 diastolic 
dysfunction. 
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Displacement of the Left Ventricle onto a steeper portion of the 
pressure-volume curve results in a shortening of the DT.13 With slower 
relaxation, the e is delayed, occurring after the E. This indicates that the LV is 
not expanding symmetrically in diastole but that propagation of filling to the 
apex and longitudinal expansion occur slowly after the LV is filled by 
movement of blood from the LA into the LV inflow tract. In the presence of 
slow relaxation, e does not occur during the time of the LA-to-LV pressure 
gradient, so e is reduced and becomes almost independent of LA pressure.16 
Both the mitral annular e and the delay in e relative to E correlate with the 
time constant of LV isovolumetric pressure decline.16,24 Thus, the pseudo 
normal mitral inflow pattern is distinguished from normal by a reduced and 
delayed e and increase in the E/e ratio. 
With even more severe diastolic dysfunction with due course of time 
due to the markedly slowed relaxation and elevated LA pressure, the E 
increases further, DT becomes very short, and e is further reduced and 
delayed, resulting in a marked elevation of E/e (Figures 2 and 3). With severe 
diastolic dysfunction, the late diastolic annular velocity (a) also may be 
reduced, and pulmonary venous systolic forward flow velocity is reduced and 
less than diastolic forward flow velocity. 
Other indicators of diastolic dysfunction can be obtained from color M-
mode imaging, Doppler echocardiography, and strain rate imaging.25 The 
presence of pseudo normalized and restricted filling patterns with elevated E/e 
indicates the presence of both diastolic dysfunction (impaired relaxation and 
elevated LV early diastolic pressures) and elevated LA pressure.17 In contrast, 
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the impaired relaxation pattern indicates diastolic dysfunction without a 
marked elevation in mean LA pressure. 
The measure of systolic function which has stood the test of time is the 
ejection fraction. It has been stated that one can predict the clinical outcome in 
dilated cardiomyopathy and a variety of cardiac diseases [71, 72] using this 
parameter. The ejection fraction shares a curvilinear relationship with end 
diastolic volume and an inverse correlation with after load [72]. But the 
limitation is that the normalization by end diastolic volume makes it 
insensitive to subclinical myocardial dysfunction in a normal sized heart or a 
small hypertrophied ventricle [73]. The normal sized heart of patients with 
type 2 diabetes and correspondingly over weight body habitus frequently 
results in poor delineation of the endocardial borders, which are essential pre 
requirements for estimating the ejection fraction quantitatively.  
Similarly, as discussed prior, the Doppler derived mitral valve inflow 
velocity pattern and its derivatives which are widely used as measures of 
diastolic function, have been proved difficult to comprehend because of the 
pseudo normal pattern, which defines grade 2 dysfunction, but may be 
mistaken for the normal pattern [74] ), unless  a differentiation procedure like 
Valsalva manoeuvre or  pulmonary vein flow assessment is performed.  
While the clinical, course of diastolic dysfunction is characterized by 
decreasing effectiveness of myocardial relaxation and extension associated 
with increasing left atrial pressure and size, the respective developments of 
pressure and filling cannot be mirrored by the traditional Doppler parameters. 
However, an even more important limitation is the non-quantitative pattern 
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recognition used for assessing diastolic function and the changes in the course 
of disease and during preventive therapy. 
MANAGEMENT: 
Screening: 
 Now that the occurrence of diastolic dysfunction in diabetic persons is 
found to be clearly high than the normal population, measures to treat 
appropriately should be made. As the diastolic dysfunction prevailing in 
diabetic persons is pre clinical without manifesting any symptoms regular 
screening for this defective cardiac performance using a echocardiogram is 
mandatory in decreasing morbidity and mortality in diabetic persons. 
Non pharmacological Therapy: 
General measures that may be used in the management consist of due 
monitoring of weight, attention to diet and life style, patient education, and 
close medical follow-up. Also aggressive control of hypertension, tachycardia, 
and other potential precipitants for HF decompensation should be emphasized. 
The role of exercise training was has also been explored.[49] Although there are 
no adequate clinical trials with is appropriate outcome endpoints, such as 
increased longevity, decreased symptoms, or improved quality of life, to prove 
the benefits of exercise training  definitively, several clinical and experimental 
studies have suggested that exercise training would be beneficial for such 
patients. [11] [12] [27] 
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Pharmacologic Therapy: 
Pharmacolgical  therapy of diastolic dysfunction which may proceed to 
failure if left unattended comprises of various groups of drugs namely the 
ACE inhibitors , Beta blockers, Calcium chan.nel blockers, Diuretics, Digoxin 
and other positive inotropic agents, Endothelin agonists and Aldosterone 
antagonists. The drug therapy should not be generalized instead it should be 
tailored according to the individual needs of the persons 
ACE INHIBITORS AND ARBs: 
Chronic activation of the Renin-Angiotensin-Aldosterone system has 
been shown to increase extracellular matrix fibrillar collagen and to be 
associated with increased stiffness. By altering this system, ACE-inhibitors 
and angiotensin II receptor blockers have a direct effect on cardiac 
musculature in addition to the result they have on blood pressure.  It is this 
effect which causes the decrease in LV hypertrophy, and the cardiac 
musculature is made more compliant and elastic.LV diastolic properties are 
based on myocardial stiffness which is the result of fibrosis. By judicious use 
of this group of drugs the changes in metabolism of type one collagen causing 
fibrosis is prevented.  
BETA-BLOCKERS: 
The reduction of hypertrophy of left ventricle by antihypertensive 
action of beta blockers can lead to improvement of diastolic filling.  However, 
their use in patients with advanced diastolic dysfunction (grade III or IV) must 
be done cautiously. 
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CALCIUM CHANNEL BLOCKERS: 
Although calcium channel blockers do not specifically improve 
diastolic function acutely, (14,15) it has shown to improve diastolic filling 
during exercise In persons with heart failure and normal LV systolic function 
and defective diastolic filling, this group of drugs may help during exercise 
though they may not be useful in acute stage.16) . The negative chronotropic 
action of these drugs helps by decreasing heart rate. 
NITRIC OXIDE DONORS: 
Nitric oxide (NO) is synthesized from the amino acid L- arginine by the 
actions of the enzyme NO synthase. In patients with dysfunctional 
endothelium, the loss of flow mediated and catecholamine-stimulated 
endotheilum derived relaxing factor (EDRF) release allows the constrictor 
effects of catecholamines to act unopposed. Thus, the loss of EDRF may 
contribute to impaired dilator responses of epicardial and resistance vessel and 
thereby to myocardial ischemia, which slows ventricular relaxation and 
increases myocardial wall stiffness. Previous studies also indicate that 
diastolic function of the heart appears to benefit from exogenous NO whereas 
its endogenous production does not play a major role in myocardial 
relaxation.(23,24) Similarly, NO donors have been shown to exert a relaxant 
effect on the myocardium which is associated with a decrease in LV end- 
diastolic pressure. 
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ALDOSTERONE ANTAGONIST: 
Aldosterone antagonists are found to have negative effect on growth of 
cardiac myocytes and fiboblasts. In view of this unique property, this group of 
drugs is believed to produce desirable results in diastolic properties.  
NATRIURETIC PEPTIDE: 
The natriuretic peptides are used in therapy of heart failure for their 
properties of preload reduction, vasodilation and renin suppression. Recent in 
vitro (31) and in vivo (32) studies demonstrated that brain natriuretic peptide 
(BNP) has a positive lusinotropic effect through their second messenger, 
cGMP. Clarkson et al. (33) evaluated the effects of BNP on resting and 
exercise hemodynamics and neurohormones in 6 patients with isolated 
diastolic heart failure and observed that BNP infusion causes significant 
attenuation of the rise of pulmonary capillary wedge pressure and mean 
pulmonary artery pressure during exercise without effects on resting 
hemodynamic parameters. In response to BNP infusion during exercise, 
circulating BNP levels were significantly increased while circulating 
aldosterone was suppressed, as compared with the patients who were infused 
with a placebo. Beneficial hemodynamic and neurohormonal effects during 
exercise by BNP infusion demonstrated by this study suggest possible direct 
and indirect effects to improve operant diastolic function [93] and potential 
therapy for isolated diastolic dysfunction. 
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METHODOLOGY 
 
STUDY GROUP: 
The present study comprises of 100 patients of Diabetes mellitus of 
more than five year duration, attending both Medical and Diabetology Out 
Patient Departments of Chengalpattu Government Medical College. 
STUDY SETTING: 
Hospital based 
STUDY PERIOD: 
1 year 
STUDY DESIGN: 
Cross sectional study 
STUDY POPULATION: 
Rural and suburban population in and around Chengalpattu. 
STUDY PLACE: 
Department of General Medicine, Chengalpattu Medical College, 
Chengalpattu. 
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INCLUSION CRITERIA: 
- All Type 2 Diabetes Mellitus patients of age 40 to 80 years  
- Duration more than five years 
-  Normal left ventricular systolic function  
EXCLUSION CRITERIA: 
1. Subjects with evidence of coronary artery disease - CAD [excluded by 
history of angina, chest pain, Electrocardiogram (ECG) changes and 
abnormal Treadmill test (TMT) results 
2. Subjects with evidence of valvular disease 
3.  Hypertensive 
4. Subjects with poor transthoracic ECHO window 
MATERIALS AND METHODS: 
From all patients included in the study a detailed medical history is to 
be obtained using the questionnaire. The patients are then subjected to 
physical examination which includes general examination, system wise 
examination and anthropometric evaluation including weight in kilogram. 
Electrocardiogram was done in all subjects. Biochemical  investigations 
includes collection of venous blood sample after a 12 hour fast and sending it 
to the biochemical laboratory for estimating parameters like plasma glucose 
level, total serum cholesterol (TC), High density lipoprotein (HDL) 
cholesterol, low density lipoprotein (LDL) cholesterol, very low density 
lipoprotein cholesterol (VLDL) and serum triglyceride levels (TG). 
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Two dimensional directed M mode echocardiography was performed 
on all the study patients. They were investigated in the left lateral decubitus 
position with 3.5 MHz transducer. All echocardiograms were performed by 
experienced cardiologists. 
Left ventricular systolic function is usually measured by the left 
ventricular ejection fraction (EF) and fractional shortening (FS). 
EF was determined by measuring LV volumes in apical 2 chamber 
view. Left ventricular volumes were measured by Area- Length method [12], 
both in end diastole (LVVd) and in end systole (LVVs) 
EF = LVVd – LVVs / LVVd 
The mean EF in normal population is taken as 59.2 [15,16]. EF was 
considered decreased if it was < 50 % Diastolic function was determined by 
ratio of peak early diastole velocity (E) / peak atrial filling velocity (A) of LV, 
i.e., (E/A), measured by spectral Doppler LV inflow velocity with sample 
volume at the level of mitral valve. 
Normal value of Doppler LV diastolic function index was taken as: 
Peak velocity E (m/sec): 0.61 m/sec +/- 0.14, 
Peak velocity A (m/sec): 0.48 m/sec +/- 0.14,  
E/A Ratio: 1.4 +/- 0.54 [18]. 
LV diastolic dysfunction was considered if E/A ratio was found to be 
0.8 or less. 
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STATISTICAL ANALYSIS: 
 Descriptive statistics for all data and suitable statistical tests of 
comparison to be done. Continuous variables to be analysed with the unpaired 
t-test and categorical variables to be analysed with the Chi-Square Test with 
Yates correction. Statistical significance is taken as P < 0.05.  
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RESULTS 
 
The present study comprises of 100 cases of diabetes mellitus of 5 
years or more duration attending medical and diabetology out patient 
departments during the study period of June 2014 to June 2015. 
Out of 100 diabetes patients selected for the study, correlation between 
diastolic dysfunction and seven parameters including. 
x Duration of diabetes  
x Glycaemic control  
x Age 
x Sex  
x Obesity  
x Dyslipidemia  
x Smoking  was studied.  
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1.  AGE DISTRIBUTION : 
TABLE – 1: SHOWING AGE DISTRIBUTION OF 100 CASES 
AGE (yrs) NO. OF PATIENTS PERCENTAGE 
40 – 50 51 51 % 
51 – 60 48 48 % 
61 – 70 1 1% 
TOTAL 100 100% 
 
GRAPH -1: SHOWING AGE DISTRIBUTION 
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2.  GENDER DISTRIBUTION: 
TABLE - 2: SHOWING GENDER DISTRIBUTION OF 100 CASES 
GENDER NO. OF PATIENTS PERCENTAGE 
MALE 48 48 % 
FEMALE 52 52 % 
TOTAL 100 100 % 
 
GRAPH – 2: SHOWING GENDER DISTRIBUTION 
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3.  DISTRIBUTION OF DURATION OF DIABETES: 
In the present study cases with diabetes for duration of five years or 
more are analysed. The duration was mainly distributed in the 5 – 10 years and 
11 – 15 years group. 
TABLE -3: SHOWING DISTRIBUTION OF DURATION 
DURATION NO OF PATIENTS PERCENTAGE 
5 – 10 YEARS 72 72 % 
11- 15 YEARS 28 28% 
TOTAL 100 100% 
 
GRAPH – 3: SHOWING DISTRIBUTION OF DURATION 
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4.  DYSLIPIDEMIA: 
In the present study, all patients underwent fasting lipid profile 
examination and the occurrence of dyslipidemia was studied 
TABLE – 4: SHOWING OCCURRENCE OF DYSLIPIDEMIA 
LIPID PROFILE NO. OF PATIENTS PERCENTAGE 
DYSLIPIDEMIA 72 72% 
NO DYSLIPIDEMIA 28 28% 
TOTAL 100 100% 
 
GRAPH – 4: SHOWING OCCURRENCE OF DYSLIPDEMIA 
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5.  OBESITY: 
In the current study, all cases underwent anthropometric examination 
and were classified based on their BMI as obese and non obese individuals 
TABLE -5: SHOWING OCCURRENCE OF OBESITY 
BMI NO OF PATIENTS PERCENTAGE 
OBESE 69 69% 
NOT OBESE 31 31% 
TOTAL 100 100% 
 
GRAPH – 5: SHOWING OCCURRENCE OF OBESITY 
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6. OCCURRENCE OF GLYCAEMIC CONTROL: 
Glycaemic status of cases was assessed using HbA1C measurements. 
TABLE – 6: SHOWING OCCURRENCE OF GLYCAEMIC CONTROL 
 
GLYCAEMIC 
STATUS 
NO. OF PATIENTS PERCENTAGE 
GOOD GLYCAEMIC 
CONTROL 
27 27 % 
POOR GLYCAEMIC 
CONTROL 
73 73 % 
TOTAL 100 100 % 
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GRAPH – 6: SHOWING OCCURRENCE OF GLYCAEMIC 
CONTROL 
 
  49 
 
7 . OCCURENCE OF SMOKING: 
From all cases who participated in the study, history of smoking was 
obtained. 
TABLE – 7: SHOWING OCCURRENCE OF SMOKING 
HISTORY OF 
SMOKING 
NO OF PATIENTS PERCENTAGE 
SMOKER 26 26% 
NON SMOKER 74 74 % 
TOTAL 100 100% 
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GRAPH – 7: SHOWING OCCURRENCE OF SMOKING 
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TABLE – 8: SHOWING AGE WISE DISTRIBUTION OF DIASTOLIC 
DYSFUNCTION IN DIABETIC PATIENTS 
AGE 
DIASTOLIC DYSFUNCTION 
NUMBER % IN AGE 
% IN 
DIASTOLIC 
DYSFUCTION 
40 – 50 YEARS 29 56.9% 40.3% 
51 – 60 YEARS 42 87.5% 
58.3% 
 
61 – 70 YEARS 1 100% 1.4% 
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TABLE – 9: SHOWING AGE WISE DISTRIBUTION OF NORMAL 
DIASTOLIC FUNCTION IN DIABETIC PATIENTS 
 
AGE 
NORMAL DIASTOLIC FUNCTION 
NUMBER % IN AGE 
% IN NORMAL 
DIASTOLIC 
FUNCTION 
40 – 50 YEARS 20 43.1% 78.6% 
51 – 60 YEARS 6 12.5% 21.4% 
61 – 70 YEARS 0 0% 0% 
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GRAPH – 8: AGE WISE DISTRIBUTION OF DIABETIC PATIENTS  
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GRAPH – 9: SHOWING DISTRIBUTION OF NORMAL DIASTOLIC 
FUNCTION 
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GRAPH – 10: SHOWING CORRELATION OF AGE AND DIASTOLIC 
DYSFUNCTION IN DIABETES 
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TABLE – 10: SHOWING GENDER WISE DISTRIBUTION OF 
DIASTOLIC DYSFUNCTION 
GENDER 
DIASTOLIC DYSFUNCTION 
NUMBER % IN SEX 
% IN DIASTOLIC 
DYSFUNCTION 
MALE 32 66.7% 44.4% 
FEMALE 40 76.9% 55.6% 
 
TABLE – 11: SHOWING GENDER WISE DISTRIBUTION OF 
NORMAL DIASTOLIC FUNCTION 
GENDER 
NORMAL DIASTOLIC FUNCTION 
NUMBER % IN GENDER 
% IN NORMAL 
DIASTOLIC 
FUNCTION 
MALE 16 33.3% 57.1% 
FEMALE 12 23.1% 42.9% 
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GRAPH – 11: DISTRIBUTION OF DIASTOLIC DYSFUNCTION IN 
MALES 
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GRAPH – 12: DISTRIBUTION OF DIASTOLIC DYSFUNCTION IN 
FEMALE 
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GRAPH – 13: SHOWING CORRELATION BETWEEN GENDER AND 
DIASTOLIC DYSFUNCTION 
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TABLE – 12: SHOWING CORRELATION BETWEEN DIASTOLIC 
DYSFUNCTION AND GLYCAEMIC CONTROL 
 
GLYCAEMIC 
CON-TROL 
DIASTOLIC DYSFUNCTION 
NUMBER 
% IN 
CONTROL 
% IN DIASTOLIC 
DYSFUNCTION 
YES 8 29.6% 11.1% 
NO 64 87.7% 88.9% 
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TABLE – 13: SHOWING CORRELATION BETWEEN NORMAL 
DIASTOLIC FUNCTION AND GLYCAEMIC CONTROL 
GLYCAEMIC 
CONTROL 
NO DIASTOLIC DYSFUNCTION 
NUMBER 
% IN 
CONTROL 
% IN NO 
DIASTOLIC 
DYSFUNCTION 
YES 19 70.4% 67.9% 
NO 9 12.3% 32.1% 
 
GRAPH – 14: SHOWING DIASTOLIC DYSFUNCTION AND 
GLYCAEMIC STATUS 
 
  62 
 
GRAPH – 15: SHOWING NORMAL DIASTOLIC FUNCTION AND 
GLYCAEMIC STATUS 
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GRAPH -16: SHOWING CORRELATION BETWEEN DIASTOLIC 
DYSFUNCTION AND GLYCAEMIC CONTROL 
 
GRAPH – 17: SHOWING DIASTOLIC FUNCTION IN CASES WITH 
GOOD GLYCAEMIC CONTROL 
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GRAPH 18: SHOWING DIASTOLIC FUNCTION IN CASES WITH 
POOR GLYCAEMIC CONTROL 
 
TABLE – 14: SHOWING CORRELATION BETWEEN DIASTOLIC 
DYSFUNCTION AND DURATION OF DIABETES 
DURATION 
DIASTOLIC DYSFUNCTION 
NUMBER 
% IN 
DURATION 
%IN DIASTOLIC 
DYSFUNCTION 
5 – 10 
YEARS 
46 63.9% 63.9% 
11- 15 
YEARS 
26 92.9% 36.1% 
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TABLE – 15: SHOWING CORRELATION BETWEEN NORMAL 
DIASTOLIC FUNCTION AND DURATION OF DIABETES 
DURATION 
NORMAL DIASTOLIC FUNCTION 
NUMBER 
% IN 
DURATION 
% IN NORMAL 
DIASTOLIC 
FUNCTION 
5 – 10 YEARS 26 36.1% 92.9% 
11 – 15 YEARS 2 7.1% 7.1% 
 
GRAPH – 19: SHOWING DIASTOLIC DYSFUNCTION AND 
DURATION OF DIABETES 
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GRAPH – 20: SHOWING NORMAL DIASTOLIC FUNCTION AND 
DURATION OF DIABETES 
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GRAPH – 21: SHOWING CORRELATION BETWEEN DIASTOLIC 
DYSFUNCTION AND DURATION OF DIABETES 
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TABLE – 16: SHOWING CORRELATION BETWEEN DIASTOLIC 
DYSFUNCTION AND SMOKING 
SMOKING 
DIASTOLIC DYSFUNCTION 
NUMBER 
% IN  
SMOKING 
%IN DIASTOLIC 
DYSFUNCTION 
SMOKER 18 69.2% 25% 
NON SMOKER 54 73% 75% 
 
TABLE – 17: SHOWING CORRELATION BETWEEN NORMAL 
DIASTOLIC FUNCTION AND SMOKING 
SMOKING 
NORMAL DIASTOLIC FUNCTION 
NUMBER 
% IN 
SMOKING 
% IN NORMAL 
DIASTOLIC 
FUNCTION 
SMOKER 8 30.8% 28.6% 
NON SMOKER 20 27% 71.4% 
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GRAPH –22: SHOWING DIASTOLIC DYSFUNCTION AND 
SMOKING 
 
GRAPH – 23: SHOWING NORMAL DIASTOLIC FUNCTION AND 
SMOKING 
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GRAPH – 24: SHOWING CORRELATION BETWEEN DIASTOLIC 
DYSFUNCTION AND SMOKING 
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GRAPH – 25: SHOWING DIASTOLIC DYSFUNCTION IN SMOKERS 
 
GRAPH – 26: SHOWING DIASTOLIC DYSFUNCTION IN NON 
SMOKERS 
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TABLE – 18: SHOWING CORRELATION BETWEEN DIASTOLIC 
DYSFUNCTION AND DYSLIPIDEMIA 
LIPID 
PROFILE 
DIASTOLIC DYSFUNCTION 
NUMBER 
% IN LIPID 
PROFILE 
%IN 
DIASTOLIC 
DYSFUNCTION 
DYSLIPIDEMIA 63 87.5% 87.5% 
NO 
DYSLIPIDEMIA 
9 32.1% 12.5% 
 
TABLE – 19: SHOWING CO-RELATION BETWEEN NORMAL 
DIASTOLIC FUNCTION AND DYSLIPIDEMIA 
LIPID PROFILE 
NORMAL DIASTOLIC FUNCTION 
NUMBER 
% IN 
DYSLIPIDEMIA 
% IN 
NORMAL 
DIASTOLIC 
FUNCTION 
DYSLIPIDEMIA 9 12.5% 32.1% 
NO 
DYSLIPIDEMIA 
19 67.9% 67.9% 
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GRAPH – 27: SHOWING DIASTOLIC DYSFUNCTION AND 
DYSLIPIDEMIA
 
GRAPH – 28: SHOWING NORMAL DIASTOLIC FUNCTION AND 
DYSLIPIDEMIA 
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GRAPH – 29: SHOWING CORRELATION WITH 
DYSLIPIDEMIA
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GRAPH – 30: SHOWING DIASTOLIC DYSFUNCTION IN 
DYSLIPIDEMIC CASES 
 
GRAPH – 31: SHOWING DIASTOLIC DYSFUNCTION IN CASES 
WITH NORMAL LIPID PROFILE 
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TABLE – 20: SHOWING CORRELATION BETWEEN DIASTOLIC 
DYSFUNCTION AND OBESITY 
OBESITY 
DIASTOLIC DYSFUNCTION 
NUMBER % IN OBESE 
% IN 
DIASTOLIC 
DYSFUNCTION 
OBESE 56 81.2% 77.8% 
NOT OBESE 16 51.6% 22.2% 
 
TABLE – 21: SHOWING CORRELATION BETWEEN NORMAL 
DIASTOLIC FUNCTION AND OBESITY 
OBESITY 
NORMAL DIASTOLIC FUNCTION 
NUMBER % IN OBESITY 
% IN NORMAL 
DIASTOLIC 
FUNCTION 
OBESE 13 18.8% 46.4% 
NON OBESE 15 48.4% 53.6% 
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GRAPH – 32: SHOWING DIASTOLIC DYSFUNCTION AND 
OBESITY 
 
GRAPH – 33: SHOWING NORMAL DIASTOLIC FUNCTION AND 
OBESITY 
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GRAPH – 34: SHOWING CORRELATION BETWEEN DIASTOLIC 
DYSFUNCTION AND OBESITY 
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GRAPH – 35: SHOWING DIASTOLIC DYSFUNCTION IN OBESE 
CASES 
 
GRAPH – 36: SHOWING DIASTOLIC DYSFUNCTION IN NON 
OBESE CASES 
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DISCUSSION 
 
 Diabetes mellitus per se is a well known independent risk factor for 
cardio vascular disease. The most common changes in cardiovascular system 
associated with diabetes are left ventricular mass and structural changes, 
negative affection of the mid wall systolic mechanics and diastolic 
dysfunction. 
 Asymptomatic diastolic dysfunction is quite common among the 
population of type 2 diabetes mellitus patients. Various co- existing states like 
advancing age, obesity and dyslipidemia and risk factors like smoking have 
both independent and additive effect over occurrence of diastolic dysfunction 
in the diabetes patients. 
The asymptomatic diastolic dysfunction in diabetes precedes systolic 
dysfunction and is a common echocardiographic finding in diabetes patients 
with normal left ventricular systolic function. 
Various diagnostic modalities like echocardiography, electro 
cardiogram and radio nuclide scans which can be categorized as invasive and 
non invasive can be utilized for identifying, assessing and quantifying the 
diabetes associated changes in cardiovascular system among which our study 
focuses on evaluating diastolic dysfunction using echocardiography . 
Echocardiography has emerged as an excellent non- invasive diagnostic 
tool to delineate the details of the structure of the cardiac cavity, dimensions of 
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cardiac walls and the wall movements. This is the reason why 
echocardiography is now widely as a tool for assessing cardiac performance 
and cardiac structural abnormalities.  
Left ventricular diastolic dysfunction has now emerged as a leading 
cause of cardiac morbidity in the Diabetes patients. The rate of association of 
defective diastolic performance, especially even in the asymptomatic stages is 
calculated to be high on the basis of available data.  
Numerous parameters like myocardial compliance and relaxation, atrial 
contraction, pre load, trans valvular pressure gradient, passive elastic 
properties, restraint of pericardium and the thoracic cage, respiratory variant, 
valve incompetence and arrhythmias influence the function of heart during 
diastolic phase.  
The development or progression of diastolic dysfunction can be 
discussed in mainly three stages which are as follows: (1) reduction in the 
early ventricular filling phase leading to inversion of ratio of peak early to 
peak atrial velocity curve, (2) increased filling pressures in the atrial and 
ventricular chambers and reduction in ventricular relaxation causing Pseudo 
normalisation of E/A flow pattern, (3) restrictive pattern development due to 
various degrees of involvement of atrial flow.  
Thus, a normal E/A flow pattern may be difficult to interpret as it may 
be associated with normal cardiac function or it may be associated with 
progressive diastolic cardiac dysfunction with raised filling pressures.  
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Takeda et al.[20] by a study conducted in  544  Japanese DM patients 
with ejection fraction  50%, found that diastolic dysfunction (impaired 
relaxation) plays a vital role in the induction of HF with normal systolic 
function in DM patients, regardless of the severity of DM and renal 
dysfunction.  
 Boyer et al.[18] stated that the prevalence of LV diastolic dysfunction 
persons without symptoms and hypertension but having type 2 diabetes 
disease is high. Diastolic dysfunction was found in 75% of the persons 
subjected to their study. In our study, prevalence of diastolic dysfunction was 
72% in asymptomatic and normotensive patients out of the total 100 persons 
subjected to study. 
In the current study, out of 100 patients who were subjected to the 
study, 73 % had poor glycaemic control and only 27%  had good glycaemic 
control as measured using reliable parameters like HbA1C.  
Among the total 72 patients who had diastolic dysfunction, 64 patients 
which accounts for 87.7 % in the total had poor glycaemic control. Also when 
assessed for correlation between glycaemic control and diastolic dysfunction 
the obtained value in the present study is ‘P’ < 0.002. This result is in 
concordance with study results of  Soldatos  et al.[8] who in their case control 
study of 55 individuals with type -2 DM concluded that diastolic dysfunction, 
present in a significant proportion of  diabetic persons.  
Van Heerebeek et al.[10] who conducted study  in 36 type -2 DM 
patients concluded that, the resting tension of cardiac myocyte is more reliable 
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when LVEF is normal. Excessive diastolic left ventricular stiffness is an 
important contributor to heart failure in diabetic persons. Diabetes is presumed 
to increase stiffness through myocardial deposition of collagen and advanced 
glycation end products. Also, in our current study, 72 % of the diabetes 
patients were found to have diastolic dysfunction with normal LVEF. 
Annonu et al. [12] in their case control study of 66 subjects found that 
there was an inverse correlation between the duration of diabetes and E/A ratio 
(r = -0.4, ‘P’ <.005). This result is comparable to our present study where 
among total 72 patients with diastolic dysfunction, 92.9 % i.e 26 of total 28 
patients with duration of diabetes more than 10 years had diastolic 
dysfunction. Also in the total 72 patients with duration of diabetes of 5 – 10 
years, 46 patients i.e 63.9 % had diastolic dysfunction. Also the correlation 
between duration duration of diabetes and diastolic dysfunction was calculated 
in present study as ‘P’ <0.004 
Masugata et al.[11] who conducted a  case control study in 77 persons 
with no hypertension patients found that, the cardiac diastolic dysfunction 
without LV systolic dysfunction in patients with type 2 DM with good 
glycaemic control is related neither to LV hypertrophy nor to hypertension, 
but rather to aging and the duration of type 2 DM. Similarly, in our current 
study, 72% of total subjects without hypertension and CAD had diastolic 
dysfunction with normal Left Ventricular systolic function. 
From et al.[2] in their study of 484 subjects between 1996 to 2007 year 
found that a duration of diabetes   4 years was independently associated with 
LV diastolic dysfunction (E/e’ >15) with odds ratio 1.91. 
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Mishra et al [7] in their case control study of 71 subjects with type 2 
DM found that asymptomatic diabetic patients have reduced LV systolic and 
diastolic function as compared with healthy subjects .  
In the current study, out of 100 patients, 51 belonged to age group of 
40–50 years and among them 29 persons that is 56.9 % had diastolic 
dysfunction. In the age group of 51 – 60 years, 48 persons were studied and 
among them 42 persons that is 87.5 % were evaluated to have diastolic 
dysfunction. As the number of patients studied above this age group were 
meagre, the results could not be extended. 
With the available data from present study, it is seen that there is strong 
co-relation between age and diastolic dysfunction with a value of ‘P’ < 0.003. 
Whether this correlation could be solely attributed to age factor or due to 
additive effect of increase in the duration of diabetes with advancing age could 
not delineated by the present study as all cases studied were diabetes patients. 
So far, various studies have shown various degrees of association 
between gender and diastolic dysfunction. In the present study, out total 
subjects 72% had diastolic dysfunction. Among them 55.6% were females and 
44.4% were males. When calculated for correlation between gender and 
diastolic dysfunction the obtained value ‘ P’  <0.254. Thus, present study does 
not show a strong association between gender and diastolic dysfunction. 
According to present study, out of total subjects 69% were obese and 
31% were not obese. Among the obese individuals who participated in the 
present study, 81.2% had diastolic dysfunction. Out of total 72 individuals 
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who had diastolic dysfunction, 77.8% that is 56 persons come under obese 
category whereas 22.2% that is 16 persons come under non obese category. 
When calculated for correlation between obesity and diastolic dysfunction, the 
obtained value is ‘ P’ < 0.002 showing strong correlation between obesity and 
diastolic dysfunction.  
Peterson et al2 designed a study to determine the effects of obesity on 
LV structure and function in obese individuals. Fifty-one subjects were 
evaluated and among them 20 were obese having BMI 30 kg/m2 and their 
LV structure and diastolic function was evaluated by 2D-echo. The result 
showed that subjects who were obese had higher and septal and posterior wall 
thickness during diastolic phase. 
Grandi et al11 evaluated the influence of obesity on LV diastolic 
function. They selected 32 non obese, 32 obese normotensives matched for 
age, sex and BMI. Results showed the main effect was found for obesity on 
LV diameter and LV mass, LV systolic function was normal in all the subjects 
and LV diastolic function was significantly reduced. They concluded that 
obesity is associated with a preclinical impairment of LV diastolic function. 
Results from the above studies are in concordance of those of our 
present study which too shows a significant correlation between obesity and 
diastolic dysfunction.  
From the data available from the present study, out of total 72 
individuals who had diastolic dysfunction, 87.5% that is 63 persons had 
dyslipidemia and 12.5% that is 9 persons were found to have normal lipid 
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profile. When calculated for association between dyslipidemia and diastolic 
dysfunction, the obtained value is ‘P’ < 0.05 showing a strong co-relation 
between dyslipidemia and diastolic dysfunction.  
Fukuta et al (12) studied the correlation between dyslipidemia and 
diastolic dysfunction in 45 age and sex matched cases and controls with 
dyslipidemia and normal lipid profile and found that there is high association 
between dyslipidemia and diastolic dysfunction. Result from this study is in 
concordance of those of our present study which also shows a significant 
correlation between obesity and diastolic dysfunction.  
Garcia et al (8) conducted a study wherein 78 matched cases who were 
smokers and 78 controls who were non smokers were included. Cardiac 
performance of all the subjects was assessed using standardised 
echocardiographic parameters.  
Results of the above study    showed there is decline in the cardiac 
performance in the case group when compared to the control group as evident 
by increase in left ventricular mass and stiffness and poor wall compliance 
leading to diastolic dysfunction.  
In the present study, out of 100 subjects studied only 26% were 
smokers and the remaining 74% were non smokers. Among the 72 individuals 
who were found to have diastolic dysfunction by echocardiographic 
parameters, 18 persons that is 25% were smokers and 54 persons that is 75% 
were non smokers.   
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When calculated for association between smoking and diastolic 
dysfunction the value obtained is ‘P’ >0.05 showing no significant correlation 
between these cause and effect. Many reasons may be attributed for this result.  
Among the total study population the number of subjects with history 
of smoking was only 26%. Gender distribution with a female preponderance 
among the study population may also contribute as in a country like India the 
habit of smoking among the female population is low when compared to other 
nations. All these factors may have lead to the negative correlation between 
smoking and diastolic dysfunction in the present study.  
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CONCLUSION 
 
The prevalence of diastolic dysfunction in asymptomatic type 2 DM 
patients is high and found to be 72% in the present study.  
The occurrence of diastolic dysfunction seems to preceed the 
occurrence of systolic dysfunction in diabetes patients. 
There is a significant correlation between duration of diabetes, 
glycaemic control, age, obesity, dyslipidemia and diastolic dysfunction among 
the seven parameters considered in the present study.  
Persons with type 2 diabetes mellitus should be screened with 
echocardiography for subclinical diastolic dysfunction.  
Early diagnosis and initiation of appropriate treatment for diastolic 
dysfunction would slow down the progression to diastolic heart failure and 
cause significant reduction in the morbidity and mortality in patients with 
diabetes.  
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PROFORMA 
 
DEMOGRAPHIC DATA OF THE PATIENT: 
Name   :    OP No   : 
Age    :    Case Serial No : 
Sex   : 
Address  : 
Occupation  : 
PAST HISTORY: 
H/O DIABETES : 
DURATION OF DIABETES : 
TREATMENT FOR DIABETES : 
H/O HYPERTENSION  : 
H/O CAD    : 
PERSONAL HISTORY : 
H/O SMOKING   : 
H/O ALCOHOL CONSUMPTION : 
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ANTHROPOMETRY: 
HEIGHT IN cms  : 
WEIGHT IN kgs  : 
BMI    : 
LABORATORY INVESTIGATIONS: 
FASTING BLOOD GLUCOSE  
POST PRANDIAL BLOOD 
GLUCOSE 
 
Hb A1C  
TOTAL CHOLESTEROL  
HDL CHOLESTEROL  
LDL CHOLESTEROL  
VLDL CHOLESTEROL  
TRIGLYCERIDE  
ELECTROCARDIOGRAM  
ECHOCARDIOGRAM 
x E 
x A 
x E/A  RATIO  
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KEY TO MASTER CHART 
 
Hb A1 C Glycosylated Hemoglobin 
TC Total Cholesterol 
TGL Tiglyceride 
HDL High Density Lipoprotein 
VLDL Very Low Density Lipoprotein 
LDL Low Density Lipoprotein 
BMI Body Mass Index 
E Early Diastolic Filling 
A Atrial Contraction 
EF Ejection Fraction 
BP Blood Pressure 
DD Diastolic Dysfunction 
Y Yes 
N No 
 
 
 
Sl.no Name Age Sex Hb 
A1C 
TC TGL VLDL HDL LDL BMI Smoking Duration 
of 
diabetes 
EF E A E/A 
ratio 
DD BP 
 
1 
 
Kumudha 48 F 7.3 214 173 35 38 141 27 N 7 66 0.5 0.7 0.7 Y 110/90 
 
2 Rani 50 F 6.8 172 85 17 41 113 23 N 8 68 0.6 0.9 0.6 Y 120/90 
3 
Rajammal 50 F 7.1 176 136 27 32 117 21 N 6 68 0.9 0.7 1.2 N 110/80 
4 
Mani 60 M 6.6 193 127 25.6 53 115 27 Y 12 72 0.7 1 0.7 Y 120/90 
5 
Krishnammal 48 F 6.9 200 133 26 46 128 31 N 9 64 0.7 1 0.7 Y 110/80 
6 
Panchalai 45 F 6.5 212 173 35 51 126 29 N 6 68 0.7 0.9 0.7 Y 130/80 
7 
Valli 42 F 6.8 238 253 51 49 138 30 N 6 60 0.7 0.9 0.7 Y 110/80 
8 
Irusan 47 M 7 149 226 45 30 74 24 N 5 70 0.5 0.7 0.7 Y 120/90 
9 
Annapoorni 51 F 6.6 206 146 29 43 134 28 N 7 64 0.6 0.9 0.6 Y 110/90 
10 
Poongodai 50 F 7 176 182 36 54 86 24 N 8 58 0.5 0.6 0.8 Y 130/80 
11 
Ayisha 43 F 6.7 212 99 20 48 144 23 N 6 62 0.6 0.8 0.7 Y 110/80 
12 
Amul 49 F 7.1 239 180 36 43 160 32 Y 7 68 0.7 0.8 0.8 Y 130/80 
13 
Bomman 60 M 8.2 211 169 34 48 129 18.94 N 10 68 0.6 1.2 0.5 Y 120/90 
14 
Selvi 45 F 6.4 168 120 24 51 93 20.44 N 6 62 1.1 0.8 1.3 N 110/80 
15 
Aravalli 48 F 7.9 197 123 23 54 120 18.97 N 7 71 0.6 0.9 0.6 Y 110/80 
16 
Vijaya 49 F 7.6 194 186 37 44 113 25 N 7 66 0.7 1 0.7 Y 120/70 
17 
Mohan 45 M 7.4 201 200 40 40 121 23.52 Y 6 58 0.9 1.2 0.75 Y 120/90 
 Sl.no Name Age Sex Hb A1C TC TGL VLDL HDL LDL BMI Smoking 
Duration 
of 
diabetes 
EF E A E/A ratio DD BP 
18 
Namadev 50 M 6.5 189 122 25 68 96 25.54 N 8 64 0.6 0.4 1.5 N 110/90 
19 
Poongodi 48 F 7.6 190 120 24 58 108 24.79 N 7 62 0.5 0.8 0.6 Y 120/60 
20 
Manohar 51 M 8.1 184 206 41 45 98 20.75 N 6 62 0.7 0.5 1.4 N 110/90 
21 
Susila 50 F 6.4 207 220 44 60 103 31.11 N 6 66 0.7 0.6 1.1 N 120/80 
22 
Meenatchi 48 F 6.2 193 127 25.6 54 114 25.8 N 7 68 1.1 1.1 1 N 130/80 
23 
Mansur ahmed 49 M 6.3 193 186 37 54 102 25.39 Y 8 66 1 0.6 1.66 N 120/90 
24 
Rani 45 F 6.9 235 143 29 75 131 26.4 N 6 66 0.7 0.8 0.8 Y 110/80 
25 
Malliga 49 F 7.8 171 200 40 35 96 21.09 N 6 68 0.7 0.6 1.16 N 120/70 
26 
Ramesh 51 M 8.3 122 120 24 58 100 13.81 Y 7 64 0.6 0.5 1.2 N 100/80 
27 
Kumaran 48 M 7.6 198 204 41 67 90 15.66 Y 8 64 0.9 0.5 1.8 N 110/90 
28 
Arputhamani 45 M 7.9 196 186 37 42 117 21.84 Y 6 73 0.6 0.8 0.75 Y 120/80 
29 
Raja 49 M 7.1 208 120 24 46 138 22.95 Y 9 66 0.6 0.8 0.75 Y 130/90 
30 
Jayaraman 50 M 6.3 160 120 24 40 94 24.44 N 8 64 0.9 0.7 1.28 N 100/80 
31 
Alamelu 51 F 6.2 312 208 42 38 128 23.68 N 6 70 0.9 1 0.8 Y 110/90 
32 
Govindhammal 50 F 7.7 251 196 49 54 148 25.41 N 11 68 0.7 0.6 1.16 N 120/90 
33 
Lakshmi 52 F 7.4 187 200 40 54 93 23.55 N 10 74 0.9 0.7 1.28 N 110/90 
34 
Kumar 50 M 8.9 247 186 37.2 31.8 178 25.49 Y 9 64 0.6 0.8 0.75 Y 130/90 
Sl.no Name Age Sex Hb A1C TC TGL VLDL HDL LDL BMI Smoking 
Duration 
of 
diabetes 
EF E A E/A ratio DD BP 
35 
Rajan 55 M 7.5 238 212 42.4 26.6 169 26.02 Y 11 60 0.6 0.8 0.75 Y 110/90 
36 
Ravi 48 M 6.4 143 172 34 49 60 27.81 Y 6 63 0.6 0.5 1.2 N 120/70 
37 
Kavitha 49 F 6.6 198 200 40 36 95 21.42 N 8 68 1.1 1.1 1 N 130/80 
38 
Gowri 60 F 7.8 209 110 22 45 142 26.81 N 7 68 0.7 0.8 0.8 Y 100/80 
39 
Manikandan 55 M 6.4 196 150 30 53 113 31 N 9 66 0.7 0.6 1.16 N 110/90 
40 
Geetha 63 F 7.9 262 196 49 49 164 29 Y 11 70 0.5 0.8 0.6 Y 110/70 
41 
Narayanan 65 M 7.5 241 185 37 47 157 28.84 N 14 58 0.5 0.6 0.8 Y 120/80 
42 
Ellappan 68 M 8.1 302 198 39 46 217 31 Y 13 53 0.5 0.8 0.62 Y 120/70 
43 
Perumal 59 M 7.6 189 176 35 38 116 33.34 N 11 71 0.7 0.9 0.77 Y 110/80 
44 
Hari 63 M 7.4 206 178 35.6 43 127.4 29.5 Y 9 62 0.9 1 0.8 Y 110/90 
45 
Nandhini 44 F 6.5 186 147 29.4 46 110 24.1 N 6 73 1 0.6 1.6 N 120/60 
46 
Devi 47 F 6.4 160 138 27.4 51 81.4 22.3 N 6 64 0.8 0.6 1.33 N 110/70 
47 
Vishwalingam 55 M 8 241 199 40 46 155 32.3 Y 9 73 0.5 0.6 0.8 Y 120/60 
48 
Venkatesan 53 M 8.2 207 177 35.4 43 128.4 31.8 Y 11 68 0.7 0.8 0.8 Y 110/70 
49 
Jayakumar 46 M 6.5 190 179 36 47 107 31.9 Y 6 78 0.9 1 0.8 Y 110/90 
50 
Muniyammal 58 F 8.8 230 165 33 41 156 33.4 N 8 61 0.5 0.6 0.8 Y 120/90 
51 
Ranjani 48 F 7.3 247 186 38 48 161 34.1 N 7 70 0.6 0.8 0.75 Y 110/60 
 Sl.no 
Name Age Sex Hb A1C TC TGL VLDL HDL LDL BMI Smoking 
Duration 
of 
diabetes 
EF E A E/A ratio DD BP 
52 
Vignesh 45 M 6.5 198 143 29 46 123 23.2 N 5 74 1 0.6 1.6 N 120/70 
53 
Rajeshwari 55 F 8 250 190 38 39 173 30.3 N 12 59 0.7 0.8 0.8 Y 110/80 
54 
Kavitha 50 F 7.6 210 170 34 43 133 29.8 N 9 64 0.8 0.9 0.8 Y 120/90 
55 
Christy 61 F 7.5 222 148 29 36 157 31.2 N 12 68 0.5 0.6 0.8 Y 110/80 
56 
Boopathy 48 M 6.5 208 152 30 41 137 25.1 Y 7 73 1 0.8 1.25 N 120/60 
57 
Mythili 51 F 7.3 312 190 38 42 232 27.2 N 8 60 0.6 0.7 0.8 Y 110/80 
58 
Mathi 50 M 7.1 248 173 35 38 175 28.1 Y 9 58 0.7 0.8 0.8 Y 120/70 
59 
Selvan 55 M 7 212 162 33 41 138 29.8 N 10 61 0.5 0.6 0.8 Y 110/80 
60 
Gomathy 61 F 7.7 181 149 30 50 101 35.1 N 11 60 0.7 0.8 0.8 Y 120/90 
61 
Prabhakar 63 M 7 311 201 40 53 218 31.2 Y 14 58 0.5 0.7 0.7 Y 110/60 
62 
Shankaran 58 M 7.8 297 199 39 49 209 30.9 Y 10 64 0.7 1.1 0.63 Y 120/60 
63 
Anandhi 43 F 7.3 198 170 34 48 116 21.8 N 8 71 0.6 0.9 0.6 Y 110/70 
64 
Iyyappan 47 M 6.7 186 180 36 51 99 26.1 Y 6 70 1 0.8 1.25 N 110/60 
65 
Sornam 54 M 8 256 179 35 39 182 27.1 Y 9 68 0.8 0.9 0.8 Y 120/90 
66 
Velu 62 M 8.1 289 193 38.6 46 204.4 33 Y 10 64 0.6 1.2 0.5 Y 110/80 
67 
Kannan 49 M 6.6 202 176 36 47 119 24 N 5 73 1 0.7 1.42 N 120/90 
68 
Eswari 41 F 6.5 193 180 36 52 95 20.1 N 5 70 1 0.6 1.66 N 120/70 
Sl.no Name Age Sex Hb A1C TC TGL VLDL HDL LDL BMI Smoking 
Duration 
of 
diabetes 
EF E A E/A ratio DD BP 
69 
Raman 46 M 7.9 294 212 42 38 214 31.4 N 7 72 0.5 0.7 0.71 Y 110/70 
70 
Wasim ali 55 M 7.7 303 199 40 44 219 32.5 N 13 62 0.7 0.8 0.8 Y 110/90 
71 
Aruna 51 F 7.3 249 206 41.2 43 164.8 34.3 N 9 64 0.8 0.9 0.8 Y 120/80 
72 
Chengalvarayan 58 M 7.8 312 218 43.6 47 221.4 32.9 N 12 54 0.5 0.6 0.8 Y 120/60 
73 
Muthu 61 M 8.2 203 195 39 42 122 27.26 Y 12 60 0.8 0.9 0.8 Y 110/90 
74 
Govindan 55 M 7.1 271 208 41.6 44 185.4 28.29 N 9 64 0.9 1.1 0.8 Y 110/70 
75 
Nagammal 58 F 7.7 243 197 39.4 46 157.6 31.24 N 11 58 0.7 0.8 0.8 Y 120/90 
76 
Kamatchi 55 F 6.6 204 153 30.6 49 124.4 22.07 N 7 71 1 0.7 1.42 N 120/70 
77 
Jaya 47 F 7.2 201 176 35.2 39 126.8 28.91 N 9 68 0.6 0.8 0.75 Y 110/60 
78 
Tamil selvi 58 F 8.1 289 205 41 46 202 31.33 N 13 62 0.6 1.2 0.5 Y 124/68 
79 
Ganesan 60 M 8.9 303 212 42.4 43 217.6 34.1 Y 11 68 0.7 0.8 0.8 Y 112/88 
80 
Mahesh 49 M 7.7 241 186 37.2 49 154.8 29.27 Y 6 74 0.9 1.2 0.75 Y 126/70 
81 
Girija 47 F 7.8 303 199 39.8 46 217.2 34.1 N 7 70 0.7 0.8 0.8 Y 112/80 
82 
Vasantha 56 F 8.1 251 212 42.4 48 160.6 27.4 N 8 68 0.6 1.2 0.5 Y 110/90 
83 
Ramesh 49 M 6.5 242 199 39.8 47 155.2 23.6 Y 6 72 1 0.8 1.25 N 120/70 
84 
Raheem 57 M 7.6 287 230 46 48 193 30.6 Y 11 70 0.6 0.8 0.75 Y 110/60 
85 
Ayisha bee 53 F 7.1 198 178 35.6 44 118.4 30.2 N 13 68 0.9 1.2 0.75 Y 120/70 
 Sl.no Name Age Sex Hb A1C TC TGL VLDL HDL LDL BMI Smoking 
Duration 
of 
diabetes 
EF E A E/A ratio DD Bp 
86 
Muthamizh 42 F 8.3 220 198 39.6 42 138.4 28.96 N 7 73 0.9 1.8 0.5 Y 110/90 
87 
Soorya moorthy 60 M 8.1 234 186 37.2 47 149.8 33.5 N 9 64 0.6 0.8 0.75 Y 120/60 
88 
Premnath 47 M 6.4 199 189 37.8 45 106 22 N 6 71 1 0.7 1.4 N 110/70 
89 
Vimala 48 F 7.9 245 204 40.8 44 161 29.8 N 8 68 0.8 0.9 0.8 Y 110/60 
90 
Annadurai 59 M 7.6 250 213 42.6 43 164.4 33.2 Y 14 72 0.7 0.8 0.8 Y 120/70 
91 
Prakash 51 M 8 243 197 39.4 48 155.6 31.8 Y 11 64 0.9 1.1 0.8 Y 110/80 
92 
Muthuram 58 M 9.1 312 260 52 43 217 23 N 8 75 0.6 0.8 0.75 Y 110/90 
93 
Subash 51 M 8.3 270 200 40 47 183 29.6 Y 7 70 0.8 1 0.8 Y 124/68 
94 
Manimegalai 54 F 7.9 264 198 39.6 46 178.4 33.4 N 13 64 0.5 0.6 0.8 Y 126/70 
95 
Balaji 42 M 6.4 196 179 35.8 46 114.2 27 N 7 72 1 0.8 1.2 N 120/90 
96 
Jayalakshmi 55 F 7.2 230 203 40.6 46 143.4 21 N 8 59 0.7 0.8 0.8 Y 124/80 
97 
Geetharani 54 F 7.8 304 250 50 43 211 29.86 N 6 68 0.8 1 0.8 Y 120/70 
98 
Nithya 51 F 7.8 256 203 40.6 43 172.4 30.8 N 7 62 0.5 0.7 0.75 Y 124/90 
99 
Anjalai 53 F 8.1 209 199 39.8 42 127.2 22 N 12 70 0.7 0.8 0.8 Y 110/90 
100 
Neela veni 52 F 7.4 308 245 49 46 213 33.6 N 11 75 0.6 0.8 0.75 Y 110/70 
 
